Cambridge, USA
Radioligand therapy (RLT) has offered a promising new approach for cancer treatment. While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients.
The ARTBIO approach is holistic. It is underpinned by a deep understanding of cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
No key contacts have been added to this profile yet.
This is the company profile page for ARTBIO on the Pharma Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.